Cartesian Therapeutics Inc (RNAC) Stock Price, Quote & News

Company Profile

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 348 8698

Website: www.cartesiantherapeutics.com

Address:

7495 New Horizon Way, Frederick, United States

YOLOartist Aug. 20 at 12:57 AM

$RNAC also, remind me SELBians, CVR’s in September? Or did Sobi put out some BS to make us wait til March? I’d love to have a good meal one of these days.

1 · Reply

YOLOartist Aug. 20 at 12:55 AM

$RNAC this is the spot where I know that I should sell and buy back in at $7 in 2 weeks, and repeat this cycle to get rich…but I won’t. But if I did sell, it would immediately shoot up to $50. I’m playing 2D checkers on a tic-tac-toe board.

1 · Reply

JuggernautRaider Aug. 19 at 6:47 PM

$RNAC

0 · Reply

kimgysen Aug. 13 at 11:05 PM

$RNAC At 90 I break even I think

1 · Reply

doDD22 Jul. 30 at 12:13 PM

$RNAC Premarket 2 share pump shenanigans as always

0 · Reply

maplelakeduckslayer Jul. 23 at 3:35 PM

$RNAC reloaded this one, very cheap with 3 major catalyst 1H next year

0 · Reply

Stock_Catcher Jul. 22 at 12:42 PM

$RNAC Thin

0 · Reply

JuggernautRaider Jul. 22 at 8:40 AM

$RNAC buying opportunities all over 🏦

0 · Reply

JuggernautRaider Jul. 21 at 10:32 AM

$RNAC i’m bullish until i’m not folks 🐂 🧬 📆

0 · Reply

JuggernautRaider Jul. 18 at 4:58 PM

$TNXP $IMRX $ALT $RNAC why hope for Irish luck? When I work hard, I tend to prosper- is that a result of luck, or simply a strong work ethic? ☘️ 💪 🇺🇸

1 · Reply

Cartesian Therapeutics Announces New Employment Inducement Grants

Aug 6, 2026, 7:00 AM EDT - 18 days ago

Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Aug 6, 2026, 7:00 AM EDT - 18 days ago

Cartesian Therapeutics Quarterly report: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 18 days ago

Cartesian Therapeutics Earnings release: Q2 2026

Jun 12, 2026, 4:05 PM EDT - 2 months ago

Cartesian Therapeutics Announces New Employment Inducement Grant

Jun 12, 2026, 10:00 AM EDT - 2 months ago

Cartesian Therapeutics Transcript: AGM 2026

Jun 9, 2026, 7:00 AM EDT - 2 months ago

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

2026-05-26T11:55:53.000Z - 3 months ago

Cartesian Therapeutics secures up to $150M financing from K2 HealthVentures

May 26, 2026, 7:00 AM EDT - 3 months ago

Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027

May 12, 2026, 7:00 AM EDT - 3 months ago

Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

2026-05-12T10:46:02.000Z - 3 months ago

Cartesian Therapeutics price target lowered to $25 from $30 at H.C. Wainwright

Apr 30, 2026, 7:00 AM EDT - 4 months ago

Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Apr 30, 2026, 7:00 AM EDT - 4 months ago

Cartesian Therapeutics Quarterly report: Q1 2026

Apr 30, 2026, 7:00 AM EDT - 4 months ago

Cartesian Therapeutics Earnings release: Q1 2026

2026-04-28T14:36:10.000Z - 4 months ago

Cartesian Therapeutics management to meet with BTIG

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Cartesian Therapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Cartesian Therapeutics Proxy statement: Proxy filing

2026-03-09T15:00:51.000Z - 6 months ago

Cartesian Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald

2026-03-09T15:00:34.000Z - 6 months ago

Cartesian Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald

2026-03-09T11:12:51.000Z - 6 months ago

Cartesian Therapeutics reports FY25 EPS ($5.02), consensus ($2.35)

Mar 9, 2026, 7:00 AM EDT - 6 months ago

Cartesian Therapeutics Earnings release: Q4 2025

Mar 9, 2026, 7:00 AM EDT - 6 months ago

Cartesian Therapeutics Annual report: Q4 2025

Mar 5, 2026, 7:00 AM EST - 6 months ago

Cartesian Therapeutics Slides: Corporate presentation

2026-01-09T13:15:20.000Z - 8 months ago

Cartesian Therapeutics highlights recent progress, outlines 2026

Jan 9, 2026, 8:04 AM EST - 8 months ago

Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook

Dec 18, 2025, 4:05 PM EST - 8 months ago

Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors

2025-11-19T11:15:25.000Z - 9 months ago

H.C. Wainwright cuts Cartesian target, calls shares ‘mispriced’

2025-11-14T12:30:28.000Z - 10 months ago

Cartesian Therapeutics price target raised to $44 from $42 at BTIG

2025-11-13T22:01:23.000Z - 10 months ago

Cartesian announces positive initial data from Phase 2 SLE trial of Descartes-08

2025-11-06T12:13:18.000Z - 10 months ago

Cartesian Therapeutics reports Q3 EPS ($1.38) vs ($1.13) last year

Nov 6, 2025, 7:00 AM EST - 10 months ago

Cartesian Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 10 months ago

Cartesian Therapeutics Quarterly report: Q3 2025

2025-10-30T11:16:19.000Z - 10 months ago

Cartesian Therapeutics appoints Brunn as Chairman of Board

Aug 28, 2025, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

2025-08-07T11:16:41.000Z - 1 year ago

Cartesian Therapeutics reports Q2 EPS 50c vs. 54c last year

2025-08-07T11:16:34.000Z - 1 year ago

Cartesian Therapeutics sees cash runway into mid-2027

Aug 7, 2025, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics Quarterly report: Q2 2025

May 30, 2025, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis

May 8, 2025, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics Earnings release: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics Quarterly report: Q1 2025

May 7, 2025, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics Slides: Corporate Presentation

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Cartesian Therapeutics Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Cartesian Therapeutics Proxy statement: Proxy Filing

Apr 8, 2025, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial

Apr 1, 2025, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 13, 2025, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics Earnings release: Q4 2024

Mar 13, 2025, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics Annual report: Q4 2024

Mar 3, 2025, 7:00 AM EST - 1 year ago

Cartesian Therapeutics Slides: Investor Presentation

Jan 27, 2025, 7:00 AM EST - 1 year ago

Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis

Dec 13, 2024, 7:00 AM EST - 1 year ago

Cartesian Therapeutics Registration statement: Registration Filing

Dec 13, 2024, 7:00 AM EST - 1 year ago

Cartesian Therapeutics Registration statement: Registration Filing

Dec 13, 2024, 7:00 AM EST - 1 year ago

Cartesian Therapeutics Registration statement: Registration Filing

Dec 3, 2024, 6:00 AM EST - 1 year ago

Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial

Nov 21, 2024, 7:00 AM EST - 1 year ago

Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit

Nov 7, 2024, 7:00 AM EST - 1 year ago

Cartesian Therapeutics Earnings release: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

Cartesian Therapeutics Quarterly report: Q3 2024

Oct 15, 2024, 7:00 AM EDT - 2 years ago

Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting

Sep 20, 2024, 8:00 AM EDT - 2 years ago

Cartesian Therapeutics Registration statement: Registration Filing

Sep 9, 2024, 8:00 AM EDT - 2 years ago

Cartesian Therapeutics Registration statement: Registration Filing

Sep 3, 2024, 7:00 AM EDT - 2 years ago

Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15

Aug 16, 2024, 8:00 AM EDT - 2 years ago

Cartesian Therapeutics Proxy statement: Proxy Filing

Aug 8, 2024, 7:15 AM EDT - 2 years ago

Cartesian Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 7:15 AM EDT - 2 years ago

Cartesian Therapeutics Earnings release: Q2 2024

Aug 2, 2024, 8:00 AM EDT - 2 years ago

Cartesian Therapeutics Registration statement: Registration Filing

Aug 2, 2024, 8:00 AM EDT - 2 years ago

Cartesian Therapeutics Proxy statement: Proxy Filing

Jul 2, 2024, 4:05 PM EDT - 2 years ago

Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik

Jul 2, 2024, 6:40 AM EDT - 2 years ago

Cartesian Therapeutics autoimmune disorder therapy meets main goal of mid-stage study

Jul 2, 2024, 6:31 AM EDT - 2 years ago

Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing

Jul 2, 2024, 6:31 AM EDT - 2 years ago

Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus

Jul 2, 2024, 6:30 AM EDT - 2 years ago

Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis

May 22, 2024, 7:00 AM EDT - 2 years ago

Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis

May 13, 2024, 4:30 PM EDT - 2 years ago

Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 8, 2024, 7:00 AM EDT - 2 years ago

Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 8, 2024, 7:00 AM EDT - 2 years ago

Cartesian Therapeutics Earnings release: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

Cartesian Therapeutics Quarterly report: Q1 2024

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Cartesian Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Cartesian Therapeutics Proxy statement: Proxy Filing

Apr 22, 2024, 4:30 PM EDT - 2 years ago

Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting

Apr 4, 2024, 7:30 AM EDT - 2 years ago

Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 28, 2024, 4:05 PM EDT - 2 years ago

Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split

Mar 7, 2024, 7:00 AM EST - 2 years ago

Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Mar 7, 2024, 6:00 AM EST - 2 years ago

Cartesian Therapeutics Annual report: Q4 2023

Mar 7, 2024, 6:00 AM EST - 2 years ago

Cartesian Therapeutics Earnings release: Q4 2023

Mar 5, 2024, 7:00 AM EST - 2 years ago

Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland

YOLOartist Aug. 20 at 12:57 AM

$RNAC also, remind me SELBians, CVR’s in September? Or did Sobi put out some BS to make us wait til March? I’d love to have a good meal one of these days.

1 · Reply

YOLOartist Aug. 20 at 12:55 AM

1 · Reply

JuggernautRaider Aug. 19 at 6:47 PM

$RNAC

0 · Reply

kimgysen Aug. 13 at 11:05 PM

$RNAC At 90 I break even I think

1 · Reply

doDD22 Jul. 30 at 12:13 PM

$RNAC Premarket 2 share pump shenanigans as always

0 · Reply

maplelakeduckslayer Jul. 23 at 3:35 PM

$RNAC reloaded this one, very cheap with 3 major catalyst 1H next year

0 · Reply

Stock_Catcher Jul. 22 at 12:42 PM

$RNAC Thin

0 · Reply

JuggernautRaider Jul. 22 at 8:40 AM

$RNAC buying opportunities all over 🏦

0 · Reply

JuggernautRaider Jul. 21 at 10:32 AM

$RNAC i’m bullish until i’m not folks 🐂 🧬 📆

0 · Reply

JuggernautRaider Jul. 18 at 4:58 PM

$TNXP $IMRX $ALT $RNAC why hope for Irish luck? When I work hard, I tend to prosper- is that a result of luck, or simply a strong work ethic? ☘️ 💪 🇺🇸

1 · Reply

JuggernautRaider Jul. 10 at 2:28 PM

$RNAC buying more

0 · Reply

laaarsas Jul. 10 at 9:15 AM

$RNAC Is this Cartesian Therapeutics?

0 · Reply

JuggernautRaider Jul. 9 at 2:32 PM

$TCRX $IONS $BMY $RNAC 😋

0 · Reply

Danzzzzzzzz Jul. 6 at 2:59 PM

$BMEA simple... $TNGX ... $1.1 in may 2025. Now around 32. $$EDSA ... 0.73 a few months ago. Rallied up to $20 a couple mobths ago. A few good ones too: $CLYM $RNAC $TECX

1 · Reply

Breton2018 Jul. 3 at 4:09 PM

$RNAC

0 · Reply

Bobsmitt333 Jun. 28 at 10:30 AM

$RNAC Sobi's next quarterly report is due for Q2 2026, typically published in late July 2026. So we finally will see how they are going to cheat us out of the CVRs?

1 · Reply

Tobyonekanobee Jun. 27 at 8:26 PM

$RNAC SELB terrible news. We have been waiting for too long already.

0 · Reply

abcdzepeda Jun. 27 at 2:27 PM

$RNAC what the heck is SOBI doing over there? How did they mess up there application to the FDA for gout? This obviously is not their first rodeo! Very frustrating that we will have to wait for them to get their act together and resubmit to the FDA.

1 · Reply

Bilipli Jun. 27 at 11:41 AM

$RNAC The FDA declined to approve NASP (formerly SEL-212) for uncontrolled gout on June 26, 2026, issuing a Complete Response Letter. The FDA cited issues with contract manufacturing facilities and manufacturing controls for the biological component, but raised no concerns regarding clinical efficacy or safety Gameover for all old stockholders,

0 · Reply

doDD22 Jun. 27 at 7:25 AM

$RNAC CVRs delayed again Might be another year if they don’t get all their ducks in a row Ignore again for another 6-12 months lol

0 · Reply

Market Cap	303.76M
Revenue (ttm)	2.80M
Net Income (ttm)	-130.30M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,653.57%
Debt to Equity Ratio	0.00

Volume	104,238
Avg Vol	214,372
Day's Range	N/A - N/A
Shares Out	30.26M
Stochastic %K	66%
Beta	0.63
Analysts	Strong Sell
Price Target	$34.57